04 September 2016
Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…) »
10 June 2016
19 May 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
17 March 2016
16 February 2016
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
07 January 2016
IntegraGen Genomics will organize an educational luncheon symposium entitled “Exomes et RNASeq : de la recherche à la recherche clinique : challenges et perspectives” during the upcoming 8èmes Assises de Génétique Humaine et Médicale being held in Lyon, France. The program will be held from 12h45 to 13h45 on (…) »
06 November 2015
Florence Pinaud’s interview with IntegraGen CEO Bernard Courtieu as a part of her story on newer genetic sequencing technologies, potential ethical issues associated with genetic sequencing, and the need for advanced data processing in association with these technologies appears (…) »
28 August 2015
Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer.
The interview (…) »
05 May 2015
Welcome to the inaugural issue of our newsletter. The goal of IntegraNews is to provide an update on the latest news and events at IntegraGen Genomics. This includes the availability of the latest technologies and molecular testing platforms in our lab and new service offerings.
Click here to download IntegraNews
22 April 2015
Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.
The first study will report results from research conducted in cooperation (…) »
